Literature DB >> 19096394

Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma.

Ettore Minutilli1, Uwe Trefzer, Eggert Stockfleth, Wolfram Sterry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19096394     DOI： 10.1038/ncponc1302

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  16 in total

1.  Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Authors:  John M Kirkwood; Ahmad A Tarhini; Stergios J Moschos; Monica C Panelli
Journal:  Nat Clin Pract Oncol       Date:  2007-11-13

2.  Why perform sentinel-lymph-node biopsy in patients with melanoma?

Authors:  Steven A Rosenberg
Journal:  Nat Clin Pract Oncol       Date:  2008-01

3.  Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

Authors:  Vernon K Sondak; Lawrence E Flaherty
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

4.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Authors:  J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

5.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.

Authors:  N Cascinelli; A Morabito; M Santinami; R M MacKie; F Belli
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

6.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

Review 7.  Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Authors:  Ronald M Bukowski; Craig Tendler; David Cutler; Esther Rose; Mark M Laughlin; Paul Statkevich
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

8.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

9.  Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.

Authors:  Daniel A Anaya; Yan Xing; Lei Feng; Xuelin Huang; Luis H Camacho; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Janice N Cormier
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

Review 10.  Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.

Authors:  Jürgen Eberle; Bahtier M Kurbanov; Amir M Hossini; Uwe Trefzer; Lothar F Fecker
Journal:  Drug Resist Updat       Date:  2007-12-03       Impact factor: 18.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.